Myovant Sciences rejects $2.5b takeover bid from Sumitovant, Sumitomo Pharma

Myovant Sciences rejects $2.5b takeover bid from Sumitovant, Sumitomo Pharma

Photo: Reuters

03 October, 2022

Myovant Sciences Sumitomo Pharma Sumitovant Biopharma

Printed by Unregistered user on Wed, 24 Dec 2025 15:52:04 GMT

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief

Subscribe to Newsletter

You may also like

Japan's Sumitomo Pharma to invest $3b for 10% stake in Swiss Roivant

Japan's Sumitomo helps factories in Southeast Asia go digital

Read more from World

Viewpoint: The structural case for APAC private credit in 2026

Blackstone to acquire Australia’s iconic Hamilton Island for $1b